Clinical Research Morus Alba Decoction Of Acute Exacerbation Of Lung Inflation Phlegm Retention In The Lung

Objective:This subject aims to sangbaipi Decoction the AECOPD Tanreyunfei retention syndrome clinical studies to observe the clinical efficacy in patients with AECOPD, the outcome of the white blood cells and neutrophils and pulmonary function. sangbaipi Decoction lung inflation attack of (AECOPD) provide the basis for the treatment of patients with the role of sangbaipi Decoction the clinical treatment of patients with lung inflation attack of (AECOPD).Methods:80cases of Tanreyunfei retention in the lung syndrome met the inclusion criteria of chronic obstructive pulmonary disease with acute exacerbation (lung inflation exacerbation of) were randomly assigned to the treating and control groups:control group of40patients given controlled oxygen, ceftazidime (right ceftazidime allergy were given cefoperazone sulbactam, or azithromycin), with levofloxacin resistance to infection; wheezing were given aminophylline, thick sputum difficult to spit were given ambroxol hydrochloride; treatment group of40patients given oral sangbaipi Decoction with Western medical treatment; observation of clinical symptoms, WBC and neutrophil ratio, pulmonary function, urine will be routine, liver, renal function, chest X-ray (CT), ECG and general safety testing.10days of a course of treatment, observation of a course. After end of treatment, the clinical efficacy and safety evaluation.Results:The two groups of patients, gender, age, smoking index, nature of work, and severity were statistically analyzed in two groups of patients no significant difference under the premise of thetreatment by the addition of sangbaipi Decoction (1) the overall clinical efficacy is the same, but the treatment group there are significant differences in the clinical control rate, markedly effective and efficient than the control group (P<0.01), indicating the treatment group, lung inflation acute exacerbation of Tanreyunfei retention permit clinical more effective than the control group.(2) After treatment, the symptoms:the treatment group, cough, sputum color, breathing, pulse, there is a significant difference (P<0.05), shortness of breath, tongue, and total score were significant differences (P<0.01), indicating the treatment group symptom improve better than the control group. White blood cell treatment group before and after treatment, P<0.01, control group before and after treatment, P<0.05;(3) the WBC level can be reduced in the two groups,but treatment group is lower than control group. It is a significant difference P<0.05; N%after treatment with the group before treatment There was a significant difference (*P<0.05), but no significant difference between the two groups. The outcome effects of the sangbaipi Decoction treatment group of white blood cells than the control group, neutrophil ratio of the treatment group compared with the control group, no significant difference.(4) pulmonary function in the treatment group and control group of patients before and after treatment (P>0.05), indicating no differences between the two groups of patients within the group and the group was not statistically significant. Note sangbaipi Decoction group and control group treatment improved lung function in the observation period no significant effect, sangbaipi Decoction group of lung function is not better than the control.Conclusion:The results of clinical studies, sangbaipi Decoction can be significantly reduced in patients with AECOPD efficacy, clinical symptoms, leukocyte outcome; during treatment for pulmonary function than the control group. In the process of medication, had no significant effect on the liver and kidney function and blood and urine routine clinical effect is significant, no significant adverse reactions, is a safe and effective route of administration.